Avvisati G, Pulsoni A, Petrucci M T, Tribalto M
Ematologia, Dipartimento di Biopatologia umana, Università La Sapienza, Roma.
Recenti Prog Med. 1990 Oct;81(10):642-50.
A dramatic improvement in the prognosis of multiple myeloma has been obtained since treatment with alkylating agents was introduced in the sixties. In recent years much effort has been made to ameliorate the obtained results by employing polychemotherapy schedules of treatment. However, no significant improvements with respect to the conventional melphalan-prednisone treatment, in terms of survival duration, have been observed. New therapeutic approaches, such as the use of biological response modifiers and the autologous or allogeneic bone marrow transplantation offer new perspectives for multiple myeloma patients. In this paper we discuss current trends in the therapy of multiple myeloma and of related complications.
自20世纪60年代引入烷化剂治疗以来，多发性骨髓瘤的预后有了显著改善。近年来，人们致力于通过采用多药化疗方案来改善已取得的治疗效果。然而，在生存时间方面，与传统的美法仑-泼尼松治疗相比，并未观察到显著改善。新的治疗方法，如使用生物反应调节剂以及自体或异基因骨髓移植，为多发性骨髓瘤患者提供了新的前景。在本文中，我们讨论了多发性骨髓瘤及其相关并发症治疗的当前趋势。
